Whalesbook
India Business Sees Strong Growth, Profits Hit by Charges
Dr. Reddy's Laboratories has achieved a significant turnaround in its India operations, reporting a 20% year-on-year sales increase in the fourth quarter of fiscal year 2026 and a 16% rise for the full year. This recovery, driven by a strategic focus on innovative products and better operational efficiency, saw India contribute about 18-19% of the company's total FY26 revenue of ₹33,593 crore. The stable domestic market provides a vital cushion against overseas market fluctuations.
However, this positive revenue trend is sharply contrasted by an 86% year-on-year drop in Q4 FY26 net profit to ₹220 crore. This decline was mainly due to substantial one-off expenses, including shelf stock adjustments, R&D impairments, and provisions for VAT liabilities and new labor codes. Consequently, profit before tax for the full year also fell 29% to ₹5,481 crore.
Chronic Therapy Gap Limits Market Position
While Dr. Reddy's is growing faster than the overall market, a critical issue lies in its portfolio's composition compared to Indian Pharmaceutical Market (IPM) trends. The IPM is increasingly shifting towards chronic therapies—such as cardiac and anti-diabetic drugs—which grew 14.2% year-on-year as of April 2026, outperforming acute therapies (7.8% growth). Chronic segments now make up over 40% of the IPM.
In comparison, Dr. Reddy's chronic therapies represent only about one-fifth of its India revenue. Analysts view this under-representation in chronic care as a major hurdle preventing Dr. Reddy's from becoming a top-tier domestic pharmaceutical player. The company's management acknowledges this imbalance and is reportedly working to strengthen its chronic therapy offerings through new product launches and potential acquisitions.
Competitive Landscape and Valuation
As of May 2026, Dr. Reddy's had a P/E ratio of approximately 17.5-19.5 and a market capitalization around ₹1.06 lakh crore. This valuation is notably lower than larger rivals like Sun Pharmaceutical Industries, which trades at a P/E of around 40.3 with a market cap of ₹4.4 lakh crore. Cipla and Zydus Lifesciences have P/E ratios closer to Dr. Reddy's, around 23-24 and 19.5 respectively, with market caps of roughly ₹1.05 lakh crore and ₹0.95 lakh crore. The broader Indian pharmaceutical market expanded by approximately 8.8% in FY26, showing a strong move towards high-value chronic treatments and the growing popularity of GLP-1 therapies for diabetes. Following its Q4 results, Dr. Reddy's shares experienced volatility, trading near 52-week lows in May 2026.
Analyst Views Lean Cautious Amid Margin Concerns
Despite the revenue rebound, the sharp drop in quarterly profitability and margin compression in Q4 FY26, driven by significant one-off charges, has led to a cautious analyst outlook. Kotak Institutional Equities maintains a 'Reduce' rating with a target of ₹1,175, citing margin misses. Morgan Stanley holds an 'Equal-weight' rating but lowered its target to ₹1,195. Goldman Sachs reiterates a 'Sell' rating with a target of ₹1,050, pointing to revenue and EBITDA margin misses linked to lower lenalidomide sales and shelf stock adjustments. Motilal Oswal rates the stock 'Neutral' with a target of ₹1,195, noting slowing earnings growth. The consensus analyst rating leans towards 'Hold' with an average target price around ₹1,293, signaling limited immediate upside potential. The persistent gap in chronic therapies remains a key structural challenge that could cap market share gains against competitors with more balanced portfolios.
Future Growth Driven by Innovation and Strategy
Dr. Reddy's aims to drive future growth and improve margins by ramping up innovative products like semaglutide and launching new biosimilars. Management guidance suggests strong pen sales for semaglutide and capacity expansion by FY28. The company's medium-term performance will depend on sustained competition for semaglutide in key markets and successful new product launches in the US, such as Abatacept. A critical strategic goal remains addressing the under-represented chronic therapy segment to achieve sustainable, broad-based growth and strengthen its position in India's evolving pharmaceutical market.